Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine
Pharmaceutical MedicinePublished 20 March 2015Open access
Peter Tormay
Citations28
SJR quartileQ1
SJR score1.11
SNIP1.18
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
With the implementation of ‘Big Data’ initiatives trying to integrate data from disparate data sources and disciplines that are available in life science, the industry has identified a new frontier that might provide the insights needed to turn the ship around and allow the industry to return to sustainable growth.
Abstract
Over the last 20 years, productivity in the pharmaceutical industry has been diminishing because of constantly increasing costs while output has overall been stagnant. Despite many efforts, productivity remains a challenge within the industry. At the same time, healthcare providers quite rightly require better value for money and clear evidence that new drugs are better than the current standard of care, making a complex situation even more complex. With the implementation of 'Big Data' initiatives trying to integrate data from disparate data sources and disciplines that are available in life science, the industry has identified a new frontier that might provide the insights needed to turn the ship around and allow the industry to return to sustainable growth.
Keywords
Computer ScienceMathematicsBiochemistry, Genetics and Molecular Biology
NatureGenome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
9,635 Citations2007Paul R. Burton, David G. Clayton +274 more
This study has demonstrated that careful use of a shared control group represents a safe and effective approach to GWA analyses of multiple disease phenotypes; generated a genome-wide genotype database for future studies of common diseases in the British population; and shown that, provided individuals with non-European ancestry are excluded, the extent of population stratification in theBritish population is generally modest.
NatureA map of human genome variation from population-scale sequencing
8,075 Citations2010Richard M. Durbin, John Burton +335 more
PubMedWhat's your strategy for managing knowledge?
4,105 Citations1999Morten T. Hansen, Nitin Nohria +1 more
The authors warn that knowledge management should not be isolated in a functional department like HR or IT, and emphasize that the benefits are greatest when a CEO and other general managers actively choose one of the approaches as a primary strategy.
Nature Reviews Drug DiscoveryHow to improve R&D productivity: the pharmaceutical industry's grand challenge
3,492 Citations2010Steven M. Paul, Daniel S. Mytelka +5 more
A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.
Nature BiotechnologyClinical development success rates for investigational drugs
2,511 Citations2014Michael Hay, David W. Thomas +3 more
The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.
Current Opinion in HIV and AIDSWhat are biomarkers?
1,998 Citations2010Kyle Strimbu, Jorge A. Tavel
Working definitions and a conceptual framework are provided to understand the roles of biomarkers in clinical research and considers select cases in which misunderstandings about the terms led to flawed research conclusions.
Nature GeneticsAssociation scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
1,375 Citations2007Paul R. Burton, Martin D. Tobin +213 more
These findings, enabled in part by increased statistical power resulting from the expansion of the control reference group to include individuals from the other disease groups, highlight notable new possibilities for autoimmune regulation and suggest that IL23R may be a common susceptibility factor for the major 'seronegative' diseases.
Nature Reviews Drug DiscoveryLessons from 60 years of pharmaceutical innovation
1,213 Citations2009Bernard Munos
Analysis of the record of pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950 shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it.
Nature Reviews Drug DiscoveryThe productivity crisis in pharmaceutical R&D
891 Citations2011Fabio Pammolli, Laura Magazzini +1 more
This study examines the decline of R&D productivity in pharmaceuticals in the past two decades and shows that this decline is associated with an increasing concentration ofR&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms.
NatureGenome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls
812 Citations2010Elaine Green, Liz Forty +215 more
A large, direct genome-wide study of association between CNVs and eight common human diseases concludes that common CNVs that can be typed on existing platforms are unlikely to contribute greatly to the genetic basis ofcommon human diseases.
Research at the University of Copenhagen (University of Copenhagen)A map of human genome variation from population-scale sequencing
542 Citations2010Richard Durbin, David L. Altshuler +360 more
The pilot phase of the 1000 Genomes Project aims to provide a deep characterization of human genome sequence variation as a foundation for investigating the relationship between genotype and phenotype, and it is shown that, because the vast majority of common variation is catalogued, over 95% of the currently accessible variants found in any individual are present in this data set.
Clinical Pharmacology & TherapeuticsDeconstructing the Drug Development Process: The New Face of Innovation
407 Citations2010Kenneth I. Kaitin
The pharmaceutical sector, as currently structured, is unable to deliver enough new products to market to generate revenues sufficient to sustain its own growth.
New England Journal of MedicineData Sharing, Year 1 — Access to Data from Industry-Sponsored Clinical Trials
102 Citations2014Brian L. Strom, Marc Buyse +2 more
Since May 2013, researchers have been able to request access to deidentified patient-level data from GlaxoSmithKline–sponsored clinical trials, subject to oversight by an independent review panel, which has been a productive first step in transparency.
Journal of Proteome ResearchThe Knowledge-Integrated Network Biomarkers Discovery for Major Adverse Cardiac Events
73 Citations2008Guangxu Jin, Xiaobo Zhou +8 more
A new approach of knowledge-integrated biomarker discovery using data from Major Adverse Cardiac Events (MACE) patients and aided by protein-protein interaction network, a new type of biomarkers are proposed, that is, network biomarkers, composed of a set of proteins and the interactions among them.
Briefings in BioinformaticsSemantic Web for Health Care and Life Sciences: a review of the state of the art
62 Citations2009Kei-Hoi Cheung, Emily Prud’hommeaux +2 more
The paper explores the nature and connectivity of several community-driven semantic warehousing projects and describes various design patterns for representing and querying provenance information relating to mapping links between heterogeneous data from sources in the domain of functional genomics.
Science Translational MedicineOpening Up to Precompetitive Collaboration
59 Citations2010Jill S. Altshuler, Erin P. Balogh +8 more
Although many of these so-called precompetitive collaborations are in the field of oncology, the lessons they offer are broadly applicable to other subfields of translational medicine.
British Journal of CardiologySwitching statins : the impact on patient outcomes
48 Citations2007Berkeley Phillips, Craig S. Roberts +4 more
Concerns for policies that encourage widespread statin switching without careful consideration of individual patient circumstances and cardiovascular risk are raised, and the need for formal trials to assess the consequences of switching statin treatment is highlighted.
Drug Information JournalVariability in Protocol Design Complexity by Phase and Therapeutic Area
39 Citations2011Kenneth Getz, R. Campo +1 more
The Tufts Center for the Study of Drug Development analyzed clinical trial protocols to benchmark protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to execute protocol procedures between 2000 and 2007.
Computational and Structural Biotechnology JournalCurrent advances in systems and integrative biology
38 Citations2014Scott Robinson, Marco Fernandes +1 more
The current approaches used in systems analysis and obstacles often encountered in large-scale data analysis and integration which tend to go unnoticed, but have a direct impact on the final outcome of a systems approach are addressed.
Cancer InformaticsNetwork-Based Identification of Biomarkers Coexpressed with Multiple Pathways
38 Citations2014Nancy Lan Guo, Ying‐Wooi Wan
JNCI Journal of the National Cancer InstituteProject Data Sphere to Make Cancer Clinical Trial Data Publicly Available
29 Citations2013Karyn Hede
The goal, according to Hugh-Jones, is to have Project Data Sphere grow into an interactive platform where investigators can learn from the collective successes and failures of previous trials with the help of powerful analytic tools, which the statistical software giant SAS Institute offered to the project free.
BMJGenomes of 100 000 people will be sequenced to create an open access research resource
27 Citations2013Ingrid Torjesen
The Personal Genome Project UK will establish the practice of open consent in the UK and enable medical advancement through meeting science’s need for ‘richer’ data.
The Capish Information Model - Simplify Access to Your Data
1 Citations2014Anna Berg, Catharina Dahlbo
The opportunities for creating clinical data transparency by integrating data to a well-defined, source-independent information model will be discussed and how challenges in protecting patient privacy and intellectual properties can be overcome.